Evidence map›Paper›PMID 33959410›Full record

ArticlePeerJ2021

Development of a single-chain fragment variable fused-mutant HALT-1 recombinant immunotoxin against G12V mutated

Michelle Yee Mun Teo, Jeremy Jeack Ceen Ng, Jung Yin Fong, Jung Shan Hwang, Adelene Ai-Lian Song, Renee Lay Hong Lim, Lionel Lian Aun In

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Advancements in antibody-drug conjugates as cancer therapeutics.Journal of the National Cancer Center · 2025
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Michelle Yee Mun TeoDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.
Jeremy Jeack Ceen NgDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.
Jung Yin FongDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.
Jung Shan HwangDepartment of Medical Sciences, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Selangor Darul Ehsan, Malaysia.ORCID 0000-0002-0908-2036
Adelene Ai-Lian SongDepartment of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, UPM Serdang, Selangor, Malaysia.
Renee Lay Hong LimDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.
Lionel Lian Aun InDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.ORCID 0000-0001-7182-112X
UCSI University · MYSunway University · MYUniversiti Putra Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsThis study aims to develop a recombinant anti-m

resultsThe V DISCUSSION: These results suggested that the development of such immunotoxins is potentially useful as an immunotherapeutic application against

Indexed as

CytotoxicG12VHALT-1HydraImmunotoxinKRASPhage displayPhagemidscfv

Identifiers

PMID33959410
PMCPMC8053384
OpenAlexW3153125295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.